Genes2Me announced Monday that it has launched its comprehensive Next-Generation Sequencing (NGS) -based panel for oncology, personalized medicine and hereditary diseases. According to the company’s press release, selectively targeting clinically important genes, these NGS panels enable comprehensive analysis with the most effective sequencing throughput. These panels are designed and validated for all common NGS platforms of Illumina, Thermo Fisher ION, and MGI, the company claims.
The company also said that the Genes2Me PAN cancer panel has coverage of 525 genes. “With just 50 ng of nucleic acid, the panel can detect the following biomarkers in a single test: single nucleotide variation (SNVs), insertion / deletion (INDELs), copy number variation (CNVs), microsatellite instability (MSI), fission and Measuring oncogenic viruses, as well as tumor mutation burden (TMB), “the IVD kit makers said in a statement.
Furthermore, liquid biopsy NGS panels for colon, breast, and lung cancers are quite unique where higher detection sensitivities can be achieved for low frequency variants from a limited amount of blood samples. Additionally, NGS panels for personalized genomics allow precise selection of prescribed drugs and the identification of genetic variants related to dosage and drug metabolism, epilepsy and anti-tuberculosis, the company claims.
Genes2Me’s Clinical Exome Sequencing (CES) Extended Panel allows for extensive genomic profiling of a variety of genetic diseases, including more than 7,500 clinically important genes not included in any other panel, the company claims. Other targeted panels for Cardiovascular Disorders, Neurological Conditions, Bleeding Disorders, Metabolic Disorders, Dermatology, etc. will also facilitate the classification of these complex conditions. All of these NGS panels are supported by automated data analysis pipelines that simplify primary, secondary and tertiary analysis.
“The new range of NGS clinical panels from Genes2Me is an exciting development in the molecular diagnostic space. To date, most diagnostic labs and hospitals have in-house next-generation sequencing platforms. Genes2Me’s clinical panels are attached to analysis pipelines that allow each NGS lab to test targets for these complex disorders (including simplified weight labs and analysis workflows) to diagnose the condition. , Enables physicians to make the right decisions for prognosis and therapy, ”said Neeraj Gupta, founder and CEO of Genes2Me.